| dc.description |
Objective New corona virus disease (COVID-19) is a respiratory disease associated with high mortality that emerged in December 2019. Individuals with preexisting health conditions, such as heart disease, hypertension, diabetes, and chronic obstructive pulmonary disease, and those with weakened immune systems are at increased risk for severe complications. Cancer patients have been adversely affected by the pandemic, both due to the disease itself and its treatments. The aim of this study is to evaluate the impact of COVID 19 on mortality in cancer patients followed in the intensive care unit (ICU). Material and Method We conducted a retrospective analysis of 275 COVID-19 patients who were admitted to the ICU between January 2020 and April 2022. Among these patients, 72 had a cancer diagnosis and were classified into two groups: Group 1 (n=203) included patients without cancer, and Group 2 (n=72) included patients with cancer. We recorded age, gender, comorbidities, PCR test results, laboratory parameters, APACHE2 and SOFA scores, duration of ICU stay, mechanical ventilation requirement, and duration of mechanical ventilation for all patients. Results Hypertension was significantly more common in Group 1 compared to Group 2 [97 (48%) and 24 (33%), respectively); p<0.05]. Serum C-reactive protein levels were significantly higher in Group 2 compared to Group 1 [144 (0.5-480) and 112 (1.1-404) mg/L, respectively; p<0.01]. Serum albumin, serum platelet and hematocrit levels were significantly lower in Group 2 compared to Group 1 [respectively 2.7 ±0.4 and 2.9 ±1.3; p <0.01], [respectively; 173 (11-557) and 212 (14-624); p <0.01], [respectively; 31.4± 7.1 and 35.8±6.6; p <0.01]. Mortality ratio was significantly lower in Group 2 compared to Group 1 [51 (71%) and 114 (56%), respectively; p=0.03]. Conclusions Our results suggest that mortality in cancer patients with COVID-19 who are admitted to the ICU is higher than in those without cancer. Further studies are needed to validate our results. |
|